Aadi Bioscience (AADI) Stock Price, News & Analysis

Company Overview

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Key Stats

• Today's Range: $1.39 to $1.51
• 50-Day Range: $1.45 to $2.86
• 52-Week Range: $1.21 to $3.81
• Volume: 54,918 shs
• Average Volume: 251,624 shs
• Market Capitalization: $35.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.67
• Consensus Rating: Hold

AADI Stock Analysis - Frequently Asked Questions

How have AADI shares performed this year?

Aadi Bioscience's stock was trading at $3.15 at the beginning of 2025. Since then, AADI shares have decreased by 54.0% and is now trading at $1.45.
View the best growth stocks for 2025 here.

How were Aadi Bioscience's earnings last quarter?

Aadi Bioscience, Inc. (NASDAQ:AADI) announced its quarterly earnings results on Tuesday, March, 18th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.37. The business earned $7.24 million during the quarter, compared to analyst estimates of $7.45 million. Aadi Bioscience had a negative net margin of 246.06% and a negative trailing twelve-month return on equity of 71.87%.
Read the conference call transcript.

When did Aadi Bioscience's stock split?

Shares of Aadi Bioscience reverse split before market open on Friday, August 27th 2021. The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Aadi Bioscience?

Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aadi Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aadi Bioscience investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Moderna (MRNA), NVIDIA (NVDA) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 3/18/2025
• Today: 4/28/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AADI
• CIK: 1422142
• Web: aadibio.com
• Phone: (424) 473-8055
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.67
• High Stock Price Target: $1.75
• Low Stock Price Target: $1.50
• Potential Upside/Downside: +14.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-65,760,000.00
• Net Margins: -246.06%
• Pretax Margin: -246.06%
• Return on Equity: -71.87%
• Return on Assets: -57.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.89
• Quick Ratio: 4.54

Sales & Book Value

• Annual Sales: $25.07 million
• Price / Sales: 1.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.29 per share
• Price / Book: 0.34

Miscellaneous

• Outstanding Shares: 24,697,000
• Free Float: 15,485,000
• Market Cap: $35.81 million
• Optionable: Optionable
• Beta: 0.68